secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001558370-25-010770
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q2 2025: Sephience approved in EU and US; total revenue $179M; net loss narrows
--------------------------------------------------------------------------------

- Sephience (sepiapterin) received EC and FDA approval with broad label for PKU across all ages and subtypes; global launch initiated.
- Q2 total revenue $178.9M (vs $186.7M Q2 2024); DMD franchise $96M: Translarna $59.5M, Emflaza $36.4M.
- Net loss improved to $64.8M from $99.2M; cash & securities $1.99B (up from $1.14B at Dec 31, 2024).
- Entered agreement to buy out Censa sales milestone obligation for $225M upfront plus future milestones.
- FY2025 revenue guidance $650-800M; vatiquinone PDUFA date Aug 19, 2025; positive Phase 2 HD results for votoplam.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/0001558370-25-010770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/tmb-20250807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer